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Abstract
Dimerization of hypoxia-inducible factor-1 beta (HIF-1b) [aryl hydrocarbon receptor nuclear translocator (ARNT)] with HIF-1a
is involved in various aspects of cancer biology, including proliferation and survival under hypoxic conditions. We
investigated the in vitro mechanism by which silencing of HIF-1b leads to the suppression of tumor cell growth and cellular
functions. Various hepatocellular carcinoma (HCC) cell lines (Huh-7, Hep3B, and HepG2) were transfected with small
interfering RNA (siRNA) against HIF-1b (siHIF-1b) and cultured under hypoxic conditions (1% O2 for 24 h). The expression
levels of HIF-1b, HIF-1a, and growth factors were examined by immunoblotting. Tumor growth was measured using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and tumor activity was measured by terminal
deoxynucleotidyl transferase dUTP nick end labeling, tumor cell invasion, and migration assays. Under hypoxic conditions,
silencing of HIF-1b expression suppressed tumor cell growth and regulated the expression of tumor growth-related factors,
such as vascular endothelial growth factor, epidermal growth factor, and hepatocyte growth factor. Suppression of tumor
cell invasion and migration was also demonstrated in HIF-1b-silenced HCC cell lines. Silencing of HIF-1b expression may
induce anti-tumor effects under hypoxic conditions in HCC cell lines.
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Introduction
Tumor hypoxia is one of the distinguished features of tumor
microenvironment found in hepatocellular carcinoma (HCC)
[1,2]. Hypoxic microenvironment usually occurs in a rapidly
proliferating tumor, mainly due to its increased metabolic rate and
oxygen consumption [3,4]. Hypoxia plays an important role in
tumor progression through angiogenesis and resistance to apop-
tosis [2]. Cellular response to hypoxia is mediated, at least in part,
by a family of transcription factors known as hypoxia-inducible
factors (HIFs) [2,3].
HIF-1 is a heterodimeric transcription factor, and is composed
of two subunits, the oxygen-sensitive HIF-1a and constitutively
expressed HIF-1b (also called the aryl hydrocarbon receptor
nuclear translocator (ARNT) [5,6]. Under low oxygen tension, the
activated transcription factor, HIF-1a, upregulates diverse hypox-
ia-inducible genes through dimerization with HIF-1b, a co-
activator of HIF-1b, and binds to the hypoxia-responsive element
in the promoter of target genes [5,6].
HIF-1b plays an important role in the differentiation and
development of many cells including T-cells, neurons, and
hepatocytes under normoxia [5]. HIF-1b together with HIF-a,
forms a complex with many other proteins and participates in
various functions in the cell [7,8]. It is also a co-activator of several
activators, and plays the role of receptor and transcription factor
by connecting activators [6,9]. Similar to HIF-1a-up regulation,
the expression of HIF-1b is increased by approximately two folds
under hypoxic conditions [10]. The interaction of HIF-1a and
HIF-1b is critical in the process of tumor survival. Although the
influences of HIF-1a on tumor cells have been widely studied [3],
the role of HIF-1b expression in tumor cell survival have been
reported in few literature and therefore remains to be investigated.
In this study, we demonstrated the effects of silencing HIF-1b
expression on HCC cells, and found that HIF-1b-silencing
regulates dimerization with HIF-1a under hypoxic conditions,
leading to the suppression of tumor cell growth, invasion, and
migration.
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Materials and Methods
Cell culture
Huh-7(KCLB60104, Korean Cell line Bank), Hep3B [11], and
HepG2(KCLB88065, Korean Cell line Bank) cells were cultured
at 37uC with 5% CO2 in Dulbecco’s Modified Eagle Medium
(DMEM; Gibco, Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS; Welgene, Daegu, Korea), 4.5 g/L glucose, L-
glutamine, and 1% penicillin/streptomycin.
small interfering RNA (siRNA) and transfection
siRNA was synthesized using the following sequences: siHIF-1a:
(Forward) 59-GUG GUU GGA UCU AAC ACU A-39, (Reverse)
59-UAG UGU UAG AUC CAA CCA C-39; siHIF-1b: (Forward)
59-CAG ACA AGC UAA CCA UCU U-39, (Reverse) 59-AAG
AUG AGC UUG UGU U-39. Cells were transfected with
respective siRNAs using Fugene HD transfection agent (Promega,
Madison, WI, USA) according to the manufacturer’s instructions.
After transfection, the cells were maintained at normoxic
conditions (21% O2) for 24 h, then replaced with fresh culture
medium, followed by 24 h of culture under hypoxic conditions
(1% O2, 5% CO2, 94% N2)
8.
Cell growth assay
Tumor cell growth rate was measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Amresco, Solon, OH, USA) assay according to the manufacturer’s
instructions. Briefly, the cells were seeded in a 96-well plate at
56103 cells/well, incubated at 37uC for 24 h, transferred to
serum-free medium, and transfected with siRNA. After incubation
at 21% O2 for 24 h, the culture medium was replace with fresh
medium supplemented with 10% FBS. Hypoxia was induced by
incubation under 1% O2 at 37uC for 24 h. After addition of MTT
to each well, the plates were incubated at 37uC for 3,4 h for
sufficient staining of cells, followed by medium removal and
dimethylsulfoxide (Sigma-Aldrich, St. Louis, MO, USA) treat-
ment. Cell viability was measured with absorbance at 595 nm
using a spectrophotometer (Molecular Devices, Toronto, Canada).
Figure 1. Suppression of tumor cell growth by silencing of hypoxia-inducible factors-1a and -1b. Huh-7 cells were transfected with small
interfering RNAs against HIF-1a, HIF-1b, or green fluorescent protein as control (siHIF-1a, siHIF-1b, and siGFP, respectively), followed by exposure at
hypoxic conditions (1% O2). (A) Tumor cell growth after silencing of HIF-1a or -1b was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Tumor cells were susceptible to growth retardation under hypoxic conditions when more than 100 nM
of siHIF-1b was transfected. However, normoxic conditions (100 nM) did not show significant difference. (B) Transfection of siHIF-1a (100 nM) or
siHIF-1b (100 nM) suppressed cell growth when maintained at hypoxic conditions. As compared to control, the growth inhibition was more
prominent with increase of siHIF-1b concentration. NT, non-target; siGFP, siRNA against green fluorescent protein; siHIF1-a, siRNA against HIF-1a;
siHIF-1b, siRNA against HIF-1b. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0103304.g001
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Real-time quantitative polymerase chain reaction (PCR)
Total RNA was extracted from HCC cells using Trizol reagent
(GIBCO BRL, Grand Island, NY, USA) according to the
manufacturer’s instructions. cDNA was synthesized from 1 mg of
RNA using reverse transcriptase (Clontech, Mountain View, CA,
USA), according to the manufacturer’s instructions. Gene
expression was measured by real-time quantitative PCR.
Immunoblot assay
The effects of silencing HIF-1a and HIF-1b expression on the
expression of proteins related to cell proliferation and angiogenesis
were assessed by immunoblot assays. Total proteins were extracted
from HIF-1a- or HIF-1b-silenced HCC cells after 24 h of hypoxia
induction. The proteins were separated according to their
molecular weight via sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to a polyvinylidene
fluoride membrane (GE Healthcare/Amersham, Buckingham-
shire, UK), and blotted with mouse monoclonal antibodies specific
for the proteins of interest. The blots were developed using the
enhanced chemiluminescence technique (PerkinElmer, Boston,
MA, USA) according to the manufacturer’s instructions, and the
level of expression of each protein was quantified and compared.
For detection of secreted proteins, enzyme-linked immunosorbent
assay (ELISA; R&D Systems, Minneapolis, MN, USA) was
performed according to the manufacturer’s instructions.
Immunoprecipitation
Total cell lysate was extracted from HCC cells using RIPA cell
lysis buffer (Cell signaling, Danver, MA, USA) according to the
manufacturer’s instructions. HIF-1a was bounded with mouse
anti-HIF-1a (Cell signaling, Danver, MA, USA) using IgG
magnetic beads (Novex, Oslo, Norway), according to the
manufacturer’s instructions. The dimerized proteins were detected
according to western blot, and blotted with the other target-mouse
monoclonal antibodies-HIF-1a (Bethyl, Montgomery, TX, USA)
specific for the proteins of interest. The blots were developed using
the enhanced chemiluminescence technique (PerkinElmer, Boston,
MA, USA) according to the manufacturer’s instructions, and the
level of expression of each protein was quantified and compared.
Tumor cell invasion assay
The effects of HIF-1a and HIF-1b knockdown on tumor cell
invasiveness were investigated in Huh-7 cells grown in serum-free
DMEM. The invasiveness of tumor cells was assessed in vitro
using a transwell chamber (Corning Costar, Cambridge, MA,
USA). Each transwell chamber was plated with 16105 cells, and
the invading cells were stained with hematoxylin and eosin. The
total number of invaded cells on the lower side of the filter was
counted under the microscope (Olympus America, Melville, NY,
USA).
Migration assay
The mobility of cells was assessed by scratch and wound healing
assay. Each experimental result was observed by optical micro-
scope.
Cell death assay
Cells were stained with FITC-labeled annexin V and propidium
iodide (PI), and tumor cell death was assessed by terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL,
Promega) assay and flow cytometry.
Statistical analysis
Results were expressed as means 6 standard error of the mean
(SEM) or frequency (%). Independent t-test was performed to
compare the difference of the mean between control and
experimental groups. All statistical analysis was done using SPSS
version 12.0 (SPSS, Inc., Chicago, IL). A p value of less than 0.05
was considered statistically significant.
Figure 2. Silencing of HIF-1b affects expression of tumor growth-related genes. Under hypoxic conditions, silencing of HIF-1b was
associated with diminished expression of several genes related to tumor growth, such as EGF and HGF, but not FGF2. NT, non-target; siGFP, siRNA
against green fluorescent protein; siHIF1-a, siRNA against HIF-1a; siHIF-1b, siRNA against HIF-1b; EGF, epidermal growth factor; HGF, hepatocyte
growth factor; FGF2, fibroblast growth factor 2. *, P,0.05.
doi:10.1371/journal.pone.0103304.g002
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Results
Silencing of HIF-1a and HIF-1b suppresses tumor cell
growth
After transfection of HCC cells with various concentrations of
siHIF-1b, tumor cell growth was assessed by MTT assay. Forty-
eight hours after transfection, tumor cell growth was significantly
suppressed as compared to control, in a dose-dependent manner.
The negative effect of HIF-1b silencing on tumor cell growth was
more prominent under hypoxic conditions, especially when more
than 100 nM of siHIF-1b or siHIF-1a was transfected to the
tumor cells (Fig. 1A, and File S1). Although the tumor cell growth
was maintained at higher doses of siHIF-1b transfection under
normoxic conditions, exposure to hypoxic environment resulted in
significant suppression of tumor cell growth. Suppression of tumor
cell growth under hypoxic conditions by HIF-1b-silencing was
more pronounced by prolonged exposure to hypoxic environment.
(Fig. 1B). Of note, consistent with the previous findings [12],
silencing of HIF-1a also displayed suppression of tumor cell
growth under hypoxic conditions, which is probably mediated by
inhibition of several other targets related to cell proliferation.
These findings demonstrate that tumor cell growth is suppressed
by silencing of HIF-1b under hypoxic conditions.
Silencing of HIF-1b affects expression of tumor growth-
related genes
Since tumor cell growth was inhibited by HIF-1b-silencing, we
measured the mRNA levels of growth factors involved in tumor
cell growth in HIF-1b-silenced tumor cells. Expression of HIF-1b
was reduced by .60% in the group treated with siHIF-1b
compared with that in the Control group, in a cell-density-
dependent manner. Therefore, siHIF-1b inhibits expression of
HIF-1b. HIF-1a expression was induced by hypoxia regardless of
HIF-1b knockdown. To determine the influence of HIF-1b
knockdown on genes related to tumor growth, the mRNA
expression levels of epidermal growth factor (EGF), fibroblast
growth factor (FGF), and hepatocyte growth factor (HGF) were
quantified by real-time quantitative PCR (Fig. 2). Under hypoxic
conditions, silencing of HIF-1b produced diminished expression of
EGF and HGF by 52% and 36% (p-value,0.05), respectively,
compared to control. However, mRNA levels of FGF2 expression
Figure 3. Silencing of HIF-1b affects protein expression and secretion of tumor growth-related genes. (A) Selective silencing of HIF-1b
protein expression by siHIF-1b was confirmed by immunoblot assays. (B) Decreased expression and secretion of EGF, HGF, and VEGF by silencing of
HIF-1a and -1b was confirmed by enzyme-linked immunosorbent assay. NT, non-target; siGFP, siRNA against green fluorescent protein; siHIF1-a,
siRNA against HIF-1a; siHIF-1b, siRNA against HIF-1b; EGF, epidermal growth factor; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth
factor. *, P,0.05.
doi:10.1371/journal.pone.0103304.g003
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was not affected by HIF-1b-silencing. Collectively, these data
suggest that under hypoxic conditions, HIF-1b expression
regulates the expression of tumor growth-related factors, namely
EGF and HGF, but not FGF2.
Silencing of HIF-1b affects protein expression and
secretion of tumor growth-related genes
Based on the aforementioned mRNA data, protein expression
of tumor growth-related genes were analyzed using Hep3B cells.
Dose-dependent and selective inhibition of HIF-1b expression by
siHIF-1b transfection was confirmed by immunoblot assays
(Fig. 3A). Interaction of HIF-1b and HIF-1a was confirmed by
immunoprecipitation (File S2). IP results demonstrated that
decreased protein expression levels of HIF-1b or HIF-1a in
HIF-1a tagged group. To determine the influence of HIF-1b
inhibition on factors related to tumor cell growth, the levels of
protein expression and secretion of EGF, HGF, VEGF, and FGF2
were analyzed (Fig. 3B). ELISA results demonstrated that
decreased protein expression levels of EGF, HGF, and VEGF in
HIF-1b-silenced cells. Of note, the expression of these molecules
was also decreased in HIF-1a-silenced cells. Notably, the
expression of FGF2 was not affected by silencing of HIF-1a or
HIF-1b. Collectively, these results demonstrate that under hypoxic
conditions, HIF-1b expression regulates the expression of various
tumor growth-related factors, namely EGF, HGF, and VEGF, but
not FGF2.
HIF-1b-silencing suppresses tumor cell invasiveness and
motility
Since tumor cells exhibit potential to mobilize and invade into
adjacent and distant regions, the effect of HIF-1b-silencing on
invasiveness and migration ability of tumor cells was studied using
various HCC cell lines. The effect of HIF-1b-silencing on the
invasiveness of tumor cells was evaluated by assessing the number
of cells that have mobilized and moved across the matrigel-coated
trans-well to the gelatin coated-bottom well. Compared to control,
siHIF-1b-silenced cells showed remarkably reduced number of
cells in the bottom well, denoting suppression of tumor cell
invasiveness (Fig. 4A). Likewise, as compared to control, markedly
diminished migration of HIF-1b-silenced Huh-7 cells was
confirmed by scratch and wound healing assay (Fig. 4B). Of note,
silencing of HIF-1a also induced suppression of tumor cell
invasiveness and migration. Together, these findings suggest that
silencing of HIF-1b affects the invasiveness and migration of
tumor cells under hypoxic conditions.
Silencing of HIF-1b sensitizes tumor cells to hypoxic
apoptosis
Normally, cells are predisposed to apoptosis upon exposure to
prolonged hypoxic environment, a phenomenon known as
hypoxic apoptosis. However, tumor cells tend to circumvent
apoptosis through various mechanisms, with the aid of the HIF
system. To evaluate whether HIF-1b is responsible for the
resistance to hypoxic apoptosis, cell death assay was performed
in HCC cells silenced for HIF-1a or HIF-1b followed by exposure
to hypoxic environment. Cell death assay demonstrated that
hypoxic apoptosis was merely induced in the control (Figure 5).
On the contrary, hypoxic apoptosis was markedly increased by
silencing HIF-1b, a finding similar to the effect of HIF-1a-
silencing on tumor cell survival. Collectively, these data suggest
that HIF-1b, along with HIF-1a, regulates hypoxic apoptosis of
tumor cells under hypoxic conditions.
Discussion
In the tumors, hypoxia is an important mechanism that induces
proliferation, metastasis, and neovascularization of tumors
Figure 4. HIF-1b-silencing suppresses tumor cell invasiveness and migration ability. (A) Compared to control, invasiveness of tumor cell
was significantly reduced in Hep3B cells transfected with siHIF-1a or -1b as demonstrated by transwell assays. (B) As compared to control, markedly
reduced migration of HIF-1a- or -1b-silenced Huh-7 cells was confirmed by scratch and wound healing assay. NT, non-target; siGFP, siRNA against
green fluorescent protein; siHIF1-a, siRNA against HIF-1a; siHIF-1b, siRNA against HIF-1b.
doi:10.1371/journal.pone.0103304.g004
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[9,13,14]. HIF-1a is a key molecule in hypoxia [12], and is known
to be involved in the proliferation of tumors and survival
mechanisms such as angiogenesis and anti-apoptosis [15]. HIF-
1a is highly regulated by oxygen concentration [12]. Under
hypoxia, HIF-1a maintained and concentrated in the cytoplasm
[10]. In normoxia, the HIF-1a proteins are rapidly degraded,
resulting in essentially no detectable HIF-1a protein [15]. On the
other hand, HIF-1b is not affected by oxygen concentration [18].
Although HIF-1a can function by forming a dimer with HIF-1b,
few studies of HIF-1b have been performed [15–18]. HIF-1b was
initially known as an ARNT factor, and plays an important role in
the differentiation and development of many cell types such as T
cells, neurons, and hepatocytes, by dimerization with AhR, which
is similar to HIF-1a [18–20]. Moreover, the AhR pathway, which
involves HIF-1b (ARNT), is known to mediate anti-tumor effects
[21]. Among high-risk patients with HCC in one study, HIF-1b
expression was high and was associated with cell cycle arrest [22].
We investigated the function of HIF-1b under hypoxic conditions.
The hypoxia response, which plays a role in tumor development,
presumably prioritizes the function of HIF-1b rather than that of
ARNT. Accordingly, further study of HIF-1b is warranted.
This study proceeded under the assumption that even when
dimerization of HIF-1a and HIF-1b is inhibited, compared with
inhibition of HIF-1a expression, the same result as expression of
HIF-1a can be obtained. As a result, siRNA inhibition of HIF-1a
and siRNA inhibition of HIF-1b were treated at equal densities,
and the present study performed the MTT assay to determine cell
growth when a hypoxic stimulus was applied. Effect of inhibition
for tumor growth similar to case of inhibition for HIF-1a could be
identified.
Based on the effect of tumor inhibition obtained from the MTT
assay, expression of the growth factors EGF, HGF, and VEGF
Figure 5. Silencing of HIF-1b sensitizes tumor cells to hypoxic apoptosis. Cell death assay demonstrated that hypoxic apoptosis was
markedly increased by silencing HIF-1b in tumor cells, a finding similar to the effect of HIF-1a-silencing on tumor cell survival. NT, non-target; siGFP,
siRNA against green fluorescent protein; siHIF1-a, siRNA against HIF-1a; siHIF-1b, siRNA against HIF-1b; PI, propidium iodide.
doi:10.1371/journal.pone.0103304.g005
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related to tumor growth through real-time quantitative PCR,
Western blotting, and ELISA was decreased [4,14]. EGF is a
growth factor that stimulates cell growth, proliferation, and
differentiation by binding to its receptor EGFR. HGF regulates
cell growth, cell motility, and morphogenesis by activating a
tyrosine kinase signaling cascade after binding to the proto-
oncogenic c-Met receptor. VEGF is a signaling protein produced
by cells that stimulates neo-vasculogenesis and angiogenesis [23].
The above three factors are all related to tumor growth and
development, and control of the expression of these three growth
factors plays an important role in anti-tumor effects. Based on
these findings, the expression of HIF-1b is inhibited and this
subsequently inhibits the formation of a dimer with HIF-1a.
Therefore, expression control of a sub-gene is another method to
inhibit the activation of tumors under hypoxic conditions.
In the present study, the influence of hypoxia on cells and that
of HIF-1b knockdown were evaluated using wound healing assay
and tumor cell invasion. When HIF-1b expression was inhibited,
wound healing was suppressed; similarly, when HIF-1a was
knocked down, motility decreased. Moreover, among various liver
cancer cell lines, only the Huh7 cell line can be used to assess
tumor invasion by measuring the degree of tumor invasiveness that
was performed using Huh7 in vitro. Further investigation is
needed to determine the cause of such a difference. The current
study evaluated the invasion degree of Huh7 cells when expression
of HIF-1b was inhibited, and the result was compared with the
group for which the expression of HIF-1a was inhibited. When the
expression of HIF-1a was inhibited, invasion did not occur as
expected. We guessed that inhibition of HIF-1b expression
prevented the formation of a dimer with HIF-1a; in turn, various
functions that should be performed under hypoxic conditions, such
as inhibited cell survival, cell motility, cell growth, and impeded
invasion.
Regarding tumor proliferation, a hypoxic state is important for
tumor growth to start. It is thought that HIF-1 expression (HIF-1a
and HIF-1b) controls the initiation of tumor growth, and can be
important in affecting anti-tumor growth by changing growth to
be more malignant in a hypoxic state. Further study is required to
determine other possible functions of HIF-1b that are compara-
tively less known than those of HIF-1a, which has drawn most of
the attention until now.
Supporting Information
File S1 Suppression of tumor cell growth by knockdown
of hypoxia-inducible factors-1a. Tumor cell growth after
knockdown of HIF-1a was measured by MTT assay. Tumor cells
were susceptible to growth inhibition under hypoxic conditions
when more than 100 nM of siHIF-1a was transfected. However,
normoxic conditions (100 nM) did not show significant difference.
(TIF)
File S2 Confirmation of dimerization with HIF-1a and
HIF-1b by Immunoprecipitation. HIF-1a was bounded with
mouse anti-HIF-1a using IgG beads. siHIF-1a or siHIF-1b group
weakly detect HIF-1a or HIF-1b band. But, HIF-1a/HIF-1b
strongly expressed over 2,3 times in the control group.
(TIF)
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